Michael Abern

Associate Professor of Urologic Oncology at Duke Cancer Institute

[Alireza Ghoreifi, MD @alirezaghoreifi]

New paper from our Duke Urology @DukeCancer group published in The Prostate journal @wileyinresearch.

Link: https://t.co/cci6ffbdhn

@michaelabern @JuddMoul @jeffkarnesMD @DrSpratticus @Davicioni

[Kidney Cancer @KidneyCancer]

👏 A great example of using outcomes that matter to patients to drive research questions. Thanks @MRHarrisonMD @DukeCancer for talking us through your poster on how quality of life influences mRCC outcomes! #ASCO26

[Dan George @Daniel_J_George]

@AarmstrongDuke presented provocative phase 2 data for a 4 drug chemo-IO regimen in NEPC, crushing historical 6 mo rPFS for platinum-based chemo (75%v55%) @DukeHealth @DukeCancer @DukeGUCancer

[Michael Abern @michaelabern]

@VickersBiostats Great point. I also meet a lot of folks who don’t know the definition of a high quality PLND which is essential to maximize the benefits

[Alireza Ghoreifi, MD @alirezaghoreifi]

Excited to be presenting at #AUA26 and catching up with colleagues and friends!
@michaelabern @DukeCancer @Hoomandjaladat @siadaneshmand @AmerUrological

[Alireza Ghoreifi, MD @alirezaghoreifi]

#AUA26 @UroOnc session - 3 papers in the past year that influenced my practice: @ClintonTim highlights our @EurUrolFocus paper on the outcomes of rob PC-RPLND for testicular cancer @Hoomandjaladat

[Hooman Ebrahimi @HoomanEbrahimii]

💡Promising work from @alirezaghoreifi and @Hoomandjaladat at #AUA2026 evaluating Bladder CARE as a non-invasive tool for UTUC diagnosis and surveillance.

🧬 Encouraging results highlighting the potential of urine-based epigenetic biomarkers in upper tract disease.

[Dan George @Daniel_J_George]

Check out the data from PSMAfore biomarker analysis: Huge prognostic significance in baseline and 6-week on treatment ctDNA levels and outcomes. Adds to PSA 50 response as well. Could guide future management in this earlier disease setting. ⁦⁦⁦@DukeCancer⁩ #GU25

[Michael Abern @michaelabern]

Our @DukeUrology team looking fresh after completing the Shakori40 trail ultra marathon relay! Best quote of the day : “Perfect day aside from all of the running “ 😅

[Michael Abern @michaelabern]

Our oncologic surgeons at @DukeUrology are looking forward to the SUO annual meeting. We are excited to discuss our fellowship program with interested resident applicants. DM me or @AnkeetShahMD to set up a meeting at SUO…

[Michael Abern @michaelabern]

@ChapinMD Difference between palpable cT3 and MRI “capsular abutment or bulging” cT3. I’m reluctant to label cT3 based on MR alone .

[Michael Abern @michaelabern]

@DukeHealth @DukeSurgery @DukeUrology @DukeHospital @DukeGUCancer I’m grateful to our clinical research and robotic surgery team for getting us started! Just the beginning….

[Michael Abern @michaelabern]

@BrantInman 2: assuming you mean phase 3 based on promising phase 1/2

[Michael Abern @michaelabern]

@BrantInman @DukeGUCancer @AmCollSurgeons @CMSGov Yes. Trying to limit outpatient radiology but balance with risk. Staging and surveillance and expected progression can be gray areas. Most agree on what is emergent.

[Michael Abern @michaelabern]

@jimhumd @nytimes I’ll go urologist = TE. Versatile,
tough, and the obvious DRE ref 🤷‍♂️

[Michael Abern @michaelabern]

@BrantInman @DukeGUCancer @AmCollSurgeons @CMSGov Thanks. We put together a surgical acuity matrix for all urologic surgery. My next challenge is trying to categorize cancer imaging. Have you guys tackled it yet ?

[Michael Abern @michaelabern]

@RealProstateDoc If it’s clear cell and the distal pancreas or SMA are involved could try to downstage with IOT (#3). If not just resect

[Michael Abern @michaelabern]

Excellent visiting professor lecture by Dr Skinner on the nuances of the AUA MIBC guidelines @UICUrol

[Michael Abern @michaelabern]

@PatrickSelph @SocietyGURS @SUO_YUO yes - that’s what I do. however, I don’t have data to support it. perhaps a higher parastomal hernia rate?